Clinical Trials
21 trialsNCT03473743 2026-03-30
A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer
Janssen Research & Development, LLC
Phase 1/2 Active not recruiting
NCT04856189 2026-01-29
Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma
University of California, Davis
Phase 1/2 Terminated
NCT03126110 2025-08-14
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT02769962 2025-07-28
Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT04383938 2025-05-13
Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
Aprea Therapeutics
Phase 1/2 Completed
NCT02365766 2025-03-18
Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects
Hoosier Cancer Research Network
Phase 1/2 Completed
NCT03190174 2025-02-17
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
Sarcoma Oncology Research Center, LLC
Phase 1/2 Completed
NCT05397171 2024-10-01
A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours
AstraZeneca
Phase 1/2 Terminated
NCT01625260 2024-07-19
A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer
Altor BioScience
Phase 1/2 Terminated
NCT03311334 2024-04-18
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
Sumitomo Pharma America, Inc.
Phase 1/2 Terminated
NCT03665285 2024-03-08
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
NextCure, Inc.
Phase 1/2 Completed
NCT03992131 2024-01-16
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)
pharmaand GmbH
Phase 1/2 Terminated
NCT04045613 2023-10-13
FIDES-02
Basilea Pharmaceutica
Phase 1/2 Completed
NCT03636256 2023-08-14
Evaluation of NanoDoce® in Participants With Urothelial Carcinoma
NanOlogy, LLC
Phase 1/2 Completed
NCT04639245 2023-08-03
Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT02983045 2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2 Completed
NCT03241173 2022-09-27
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT03277352 2021-07-22
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT03361228 2020-05-21
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors
Incyte Corporation
Phase 1/2 Terminated
NCT03123055 2020-03-18
FIERCE-22
Rainier Therapeutics
Phase 1/2 Terminated
NCT02401542 2020-03-09
FIERCE-21
Rainier Therapeutics
Phase 1/2 Terminated